Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
about
Mepolizumab versus placebo for asthmaOmalizumab for asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenSevere asthma: anti-IgE or anti-IL-5?Biologics in asthma--the next step toward personalized treatmentThe role of omalizumab in the treatment of severe allergic asthma.Evolving Concepts of Asthma.Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.Omalizumab: the evidence for its place in the treatment of allergic asthmaAnti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Novel targeted therapies for eosinophil-associated diseases and allergyRecommendation for optimal management of severe refractory asthma.Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescentsUse of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis.Pharmacotherapy of severe asthmaOmalizumab: clinical use for the management of asthma.Emerging anti-inflammatory agents for allergic rhinitis.Omalizumab in the treatment of allergic respiratory disease.Unusual asthma syndromes and their managementA phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaAnti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.Asthma treatment: 'magic bullets which seek their own targets'.Anti-immunoglobulin e therapyAnti-immunoglobulin E therapy with omalizumab for asthma.Anti-IgE in allergic asthma and rhinitis: an update.The effect of omalizumab on ventilation and perfusion in adults with allergic asthma.Asthma 2008: targeting immunoglobulin E to achieve disease control.A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.Asthma control in adolescents: role of leukotriene inhibitors.Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy.Effects of asthma treatment: the present and future.Omalizumab for pediatric asthma.CC-chemokine CCL15 expression and possible implications for the pathogenesis of IgE-related severe asthma.Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.Obesity's effect on asthma extends to diagnostic criteria.
P2860
Q24186306-153CD914-9B39-480B-9D22-4259F77C5985Q24201145-3FFD009B-EF5F-4F76-B235-B0E5E0F973AAQ24246484-F3735791-FABB-4466-BA1A-C23B98959C31Q28071832-885FC2FB-FA5C-426C-8FA5-50AE9B67ED04Q28085614-E4462225-664E-4B96-909E-26DC46756664Q33591890-D9A7E22D-D6E5-4CCD-A0F8-5B9491ADACF4Q33735605-C46B59DC-0339-4CFF-91FB-4A49AC8C5CC4Q33758358-374010B0-FB57-4324-B869-9B404A662279Q33973970-E83A14EE-3C11-4B0C-ACC2-ED2BC2289F68Q34412092-FC6DE59D-1586-449E-BA07-DC2644E93A85Q34444620-536A8E01-A8A8-4952-ACCD-6040C4DB0E7EQ34620187-12EA98B1-7917-4C5C-BD2E-377334E3B9A3Q34625206-7D44EC67-52E3-44B9-9391-2D614FA44C2AQ34627140-68CFFA1C-FED0-417B-863E-F515EF21B889Q34805259-E2493548-027F-479E-95E7-ABB75FF97F87Q34979344-56E043EC-9057-4FFE-9042-B6CE71060BB3Q35040868-7C4B915C-E886-48D7-BCAA-D96DA5CD4F60Q35322603-B1401B1F-F6AC-44F7-AE72-E1A8AF3615DCQ36055963-D012BE69-544F-461F-81C8-DE7506ED2C67Q36302823-5680E9D8-0D49-4422-B310-EC2F2F923A6FQ36414178-61748F15-8F9A-4623-967C-6A342D96BA98Q36443760-2C7A400F-521D-47F5-A05D-FD932A10A2D8Q36579400-42C31F2E-7BAB-4F2E-B760-8C32A02DBD15Q36765775-60CE8B71-E562-4632-A3E3-D7F5C9B7749BQ36825045-11E9B8F6-6392-4A57-8870-C8DE8E2BCDBFQ36834564-7E6B6A20-AE11-43BA-810C-C59C20BB5C04Q36910188-D7FAE154-87D3-4F27-A8E6-FDA8CC532396Q36981688-C437CA85-5568-46A0-8105-0694C45D05F3Q37025660-F29B9DFF-4304-462F-8213-23A9D12EC88BQ37211041-0F654C4D-A01B-430C-9A76-014EE407C86DQ37360030-7E39779C-B872-4E56-A302-4D2FD9920665Q37384805-C35EAA1A-565A-40BB-9555-07DDBDA2CED5Q37561894-E62EEEE8-989A-413F-A403-D0BC3EF19CA7Q37604549-84939BE2-6742-4697-B7A4-D889303C23D5Q37755242-874A9715-B6B6-44B3-8A83-5A3F32CEDF30Q37800937-C219CBC0-7505-45F0-962E-C90D77203E21Q38069151-6FA038E5-7D35-46A9-A111-91A97BABF418Q38599656-95BAB945-8F5B-4DD7-8EFE-928E40AD660EQ38661772-3B86E2ED-DA0E-4CD7-90A5-E79ECE1E2350Q38721003-B082C5BE-9D51-410E-BA22-883A5A9FB61A
P2860
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Predicting response to omalizu ...... patients with allergic asthma.
@ast
Predicting response to omalizu ...... patients with allergic asthma.
@en
Predicting response to omalizu ...... patients with allergic asthma.
@nl
type
label
Predicting response to omalizu ...... patients with allergic asthma.
@ast
Predicting response to omalizu ...... patients with allergic asthma.
@en
Predicting response to omalizu ...... patients with allergic asthma.
@nl
prefLabel
Predicting response to omalizu ...... patients with allergic asthma.
@ast
Predicting response to omalizu ...... patients with allergic asthma.
@en
Predicting response to omalizu ...... patients with allergic asthma.
@nl
P2093
P921
P356
P1433
P1476
Predicting response to omalizu ...... patients with allergic asthma.
@en
P2093
Howard Fox
Jean Bousquet
Peter Freeman
Sally Wenzel
William Lumry
P304
P356
10.1378/CHEST.125.4.1378
P407
P577
2004-04-01T00:00:00Z